Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC)

Condition:   Atrial Fibrillation (AF) Interventions:   Biological: Abelacimab;   Drug: Placebo Sponsor:   Anthos Therapeutics, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials